Ryota Tanaka

Ryota Tanaka

Auto-generated profile, based on publicly available information

Ryota Tanaka

Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2016 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
RTRyota Tanaka
Ryota Tanaka
HMHiroshi Maruyama
Hiroshi Maruyama
YTYasushi Tomidokoro
Yasushi Tomidokoro
KYKumi Yanagiha
Kumi Yanagiha
THTakumi Hirabayashi
Takumi Hirabayashi
MFManabu Fujimoto
Manabu Fujimoto
Nivolumab, an anti-programmed death-1-specific monoclonal antibody, has demonstrated a durable response and effect on overall survival and has become one of the standard treatments for patients with advanced melanoma. Reported herein is a case of nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy, in which an 85-year-old woman with stage IV melanoma developed grade 1 paresthesia 2 weeks after the initial dose of nivolumab was administered. With continued treatment, the neurological deficiency deteriorated rapidly, mimicking Guillain–Barré syndrome, causing such a dramatic decrease in her activities of daily living that she could no longer function in daily life. Thus, nivolumab treatment was discontinued. A course of intravenous immunoglobulin infusion yielded a dramatic clinical improvement; in particular, improved motor control was observed within a few days. Her initial presentation was suggestive of acute inflammatory demyelinating polyradiculoneuropathy, a subtype of Guillain–Barré syndrome; however, the good response to steroids and exacerbation 8 weeks after the onset were suggestive of chronic inflammatory demyelinating polyradiculoneuropathy induced by nivolumab. This is the first case of Guillain–Barré syndrome-like autoimmune polyradiculoneuropathy induced by programmed death-1/programmed death-ligand 1 inhibitors. Although neurological adverse events related to nivolumab are rare, they can become severe, requiring early diagnosis and intervention. Intravenous immunoglobulin may be considered as an effective initial treatment for patients who develop acute autoimmune nervous system disorders due to nivolumab.

29 January 2013 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
RTR. Tanaka
R. Tanaka
YSY. Sasajima
Y. Sasajima
HTH. Tsuda
H. Tsuda
KNK. Namikawa
K. Namikawa
ATA. Tsutsumida
A. Tsutsumida
NYN. Yamazaki
N. Yamazaki

11 November 2016 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
RTRyota Tanaka
Ryota Tanaka
YFYasuhiro Fujisawa
Yasuhiro Fujisawa
ISInoue Sae
Inoue Sae
HMHiroshi Maruyama
Hiroshi Maruyama
SIShusaku Ito
Shusaku Ito
MFManabu Fujimoto
Manabu Fujimoto
After 4 weeks of the last dose of nivolumab, a 59-year-old man with stage IV melanoma was subject to treatment with ipilimumab. After 5 weeks, the patient developed severe hepatitis, showing markedly elevated levels of both aspartate aminotransferase and alanine aminotransferase (>2000 U/l). Using pulse steroid therapy with 1000 mg/d of methylprednisolone, liver function initially improved, but then deteriorated upon dosage reduction. Subsequently, mycophenolate mofetil (MMF) was administered at a dose of 2 g/d in addition to the corticosteroid, which resulted in aspartate aminotransferase and alanine aminotransferase levels gradually improving to grade 1, and the corticosteroid dose was successfully reduced to 0.5 mg/kg/d of oral prednisolone. Liver function then remained stable when MMF was tapered. In conclusion, the use of MMF improved liver function in this patient with steroid-refractory hepatitis induced by immune checkpoint inhibitor administration.

15 October 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
RTRyota Tanaka
Ryota Tanaka
YIYuki Ichimura
Yuki Ichimura
NKNoriko Kubota
Noriko Kubota
ASAkimasa Saito
Akimasa Saito
YNYoshiyuki Nakamura
Yoshiyuki Nakamura
NONaoko Okiyama
Naoko Okiyama
Use of immune checkpoint inhibitors that target programmed cell death-1 (PD-1) can lead to various autoimmune-related adverse events (irAEs) including psoriasis-like dermatitis. Our observations on human samples indicated enhanced epidermal infiltration of CD8 T cells, and the pathogenesis of which appears to be dependent on IL-6 in the PD-1 signal blockade-induced psoriasis-like dermatitis. By using a murine model of imiquimod-induced psoriasis-like dermatitis, we further demonstrated that PD-1 deficiency accelerates skin inflammation with activated cytotoxic CD8 T cells into the epidermis, which engage in pathogenic cross-talk with keratinocytes resulting in production of IL-6. Moreover, genetically modified mice lacking PD-1 expression only on CD8 T cells developed accelerated dermatitis, moreover, blockade of IL-6 signaling by anti-IL-6 receptor antibody could ameliorate the dermatitis. Collectively, PD-1 signal blockade-induced psoriasis-like dermatitis is mediated by PD-1 signaling on CD8 T cells, and furthermore, IL-6 is likely to be a therapeutic target for the dermatitis.

28 November 2019 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
YNYasuhiro Nakamura
Yasuhiro Nakamura
JAJun Asai
Jun Asai
HIHiroshi Igaki
Hiroshi Igaki
TITakashi Inozume
Takashi Inozume
KNKenjiro Namikawa
Kenjiro Namikawa
MSMakoto Sugaya
Makoto Sugaya

23 March 2016 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
RTRyota Tanaka
Ryota Tanaka
YFYasuhiro Fujisawa
Yasuhiro Fujisawa
HMHiroshi Maruyama
Hiroshi Maruyama
YNYasuhiro Nakamura
Yasuhiro Nakamura
KYKoji Yoshino
Koji Yoshino
MFManabu Fujimoto
Manabu Fujimoto
Nivolumab (ONO-4538) is an anti-programmed death-1 specific monoclonal antibody, which has become a standard treatment for metastatic malignant melanoma. Nivolumab induces autoimmune adverse events, defined as immune-related adverse events. Herein, we report a case of nivolumab-induced thyroid dysfunction in the clinical setting. Fourteen patients were treated with nivolumab at our institute, of which three developed thyroid dysfunction, an incidence higher than previously reported in the initial clinical trials. Interestingly, one patient achieved complete remission; suggesting that in some patients, the occurrence of immune-related adverse events, including thyroid dysfunction, might reflect the drug's antitumour efficacy. No patient died or discontinued nivolumab treatment owing to thyroid dysfunction. Although thyroid dysfunction first appeared to be asymptomatic, two of the three patients developed symptoms related to hypothyroidism soon after, requiring hormone replacement therapy. Another patient developed hyperthyroidism that was initially asymptomatic; the patient subsequently developed myalgia with fever >39.5°C after two additional courses of nivolumab. Treatment with nivolumab was therefore discontinued, and treatment with prednisolone was initiated. Symptoms resolved within a few days, and thyroid function normalized. Thyroid dysfunction is sometimes difficult to diagnose because its symptoms similar to those of many other diseases. In addition, thyroid-related immune-related adverse events may present with unique symptoms such as myalgia with high fever, abruptly worsening patients' quality of life. Consequently, thyroid dysfunction should be considered as a possible immune-related adverse event. Thus, it is important to test for thyroid dysfunction at baseline and before the administration of each nivolumab dose if possible.